TACSTD2 and prostate cancer: Although, high expression of TROP2 has been linked to poor patient prognosis in pancreatic cancer (46), prostate cancer (47), oral squamous cell carcinomas (48), gastric cancer (49), colon cancer (50, 51), cervical cancer (52), gallbladder cancer (53) and ovarian cancer (54), while there were other studies describing associations between low TROP2 expression and poor patient prognosis in lung cancer (21, 54).